美国FDA批准Rybrevant Faspro™ (Amivantamab与Hyaluronidase-Lpuj),使其与Lazcluze® (Lazertinib) 联合使用时,成为第一线组合方案中给药时间最简、最短的选择。
美国FDA批准Rybrevant Faspro™ (Amivantamab与Hyaluronidase-Lpuj),使其与Lazcluze® (Lazertinib) 联合使用时,成为第一线组合方案中给药时间最简、最短的选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.